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Abstract
Background: Physical exercise mitigates fatigue during androgen deprivation therapy
(ADT); however, the effects of different exercise prescriptions are unknown.
Objectives: To determine the long-term effects of different exercise modes on fatigue in
prostate cancer patients undergoing ADT.
Design, setting, and participants: Between 2009 and 2012, 163 prostate cancer patients
aged 43–90 y on ADTwere randomised to exercise targeting themusculoskeletal system
(impact loading + resistance training; ILRT; n = 58), the cardiovascular and muscular
systems (aerobic + resistance training; ART; n = 54), or to usual care/delayed exercise
(DEL; n = 51) for 12 mo across university-affiliated exercise clinics in Australia.
Intervention: Supervised ILRT for 12 mo, supervised ART for 6 mo followed by a 6-mo
home program, and DEL received a printed booklet on exercise information for 6 mo
followed by 6-mo stationary cycling exercise.
Outcome measurements and statistical analysis: Fatigue was assessed using the Euro-
pean Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-
Core 36 and vitality using the Short Form-36. Analysis of variance was used to compare
outcomes for groups at 6 mo and 12 mo.
Results and limitations: Fatigue was reduced (p = 0.005) in ILRT at 6 mo and 12 mo (5
points), and in ART (p = 0.005) and DEL (p = 0.022) at 12 mo. Similarly, vitality increased
for all groups (p  0.001) at 12 mo (4 points). Those with the highest levels of fatigue
and lowest vitality improved the most with exercise (ptrend < 0.001). A limitation was
inclusion of mostly well-functioning individuals.
Conclusions: Different exercise modes have comparable effects on reducing fatigue and
enhancing vitality during ADT. Patients with the highest levels of fatigue and lowest
vitality had the greatest benefits.
* Corresponding author. ExerciseMedicine Research Institute, School ofMedical and Health Sciences,
Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia. Tel.: +61 8 63045476.
E-mail address: d.taaffe@ecu.edu.au (D.R. Taaffe).
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0302-2838/# 2017 European Association of Urology. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Androgen deprivation therapy (ADT) is extensively used in
the management of prostate cancer (PCa) but is associated
with an array of adverse effects [1]. One adverse effect
which has a considerable impact on quality of life is fatigue
and a substantial proportion of men with PCa suffer from
fatigue, with 40% or more of those on long-term ADT
reporting chronic fatigue or clinically-relevant fatigue
which interferes with daily functioning [2].
Exercise interventions have shown positive effects on
reducing or mitigating fatigue [3]. As a result, recent expert
reviews in urology/oncology have incorporated aerobic and
resistance exercise interventions as evidence-based strategies
to mitigate toxicities from ADT including fatigue [1,4]. We
[5,6] and others [7,8] have reported in relatively short-term
trials (< 6 mo) of progressive resistance (strength) training
and/or aerobic exercise consisting of walking/jogging or
cycling at moderate to high intensity can reduce or prevent
the worsening of fatigue, as can the same exercise modes
when combinedwith dietary advice/behavioural components
in a lifestyle intervention [9,10]. However, these studies have
examined only the effects of short-term interventions with
longer-term outcomes rarely reported. Importantly, advance-
ments to exercise protocols/prescription are required to
understand the potential of different exercise modalities on
fatigue. Accordingly, we report for the first time the efficacy of
a 1-y long randomised controlled trial (RCT) of varying
exercise interventions in PCa patients undergoing ADT with
changes in fatigue and vitality assessed over 6mo and 12mo.
2. Patients and methods
2.1. Patients
Two-hundred and ninety-three patients with PCa were screened for
participation from 2009 to September 2012 at Perth, Western Australia
and Brisbane, Queensland and their progress through the study is
detailed in Fig. 1. Inclusion criteria included histologically documented
PCa, minimum exposure to ADT of 2 mo, without prostate-specific
antigen (PSA) evidence of disease activity, and anticipated to receive ADT
for the subsequent 12 mo. Exclusion criteria included bone metastatic
disease, musculoskeletal, cardiovascular, or neurological conditions that
could inhibit them from exercising, inability to walk 400m or undertake
exercise, and structured resistance and aerobic training in the previous
3 mo. All participants obtained medical clearance from their physician.
The study was approved by the University Human Research Ethics
Committee and all participants provided written informed consent.
2.2. Study design and random assignment
This was a three-armed RCT. Primary endpoints were bone mineral
density and cardiovascular capacity [11], which will be reported
elsewhere, with secondary endpoints including physical function and
self-reported patient outcomes. Potential participants were primarily
identified by their treating urologist/oncologist and referred to the study
coordinator to confirm eligibility, describe the study, and obtain informed
consent. Study patients underwent a familiarisation session that included
correct exercise technique followed by baseline testing comprising
physical tests, questionnaires, and a venous blood sample. Following
baseline assessment, participants were stratified according to time on
ADT (< 6 mo or  6 mo) and randomly allocated to: impact
loading + resistance training (ILRT), aerobic + resistance training (ART),
or to usual care/delayed exercise (DEL) by computer random assignment.
2.3. Exercise training program
ILRT was undertaken twice weekly in University-affiliated exercise
clinics for 12 mo. Sessions were supervised with up to 10 participants.
The impact-loading component consisted of a series of bounding,
skipping, drop jumping, hopping, and leaping activities that produced
ground reaction forces of 3.4–5.2 times body weight, and was
progressive in nature. Specific details on progression are described
elsewhere [11]. Resistance training consisted of six principal exercises
that targeted the major upper and lower body muscle groups: chest
press, seated row, shoulder press, leg press, leg extension, and leg curl,
with supplementary exercises. Patients performed two to four sets of
each exercise at an intensity of 6–12 RM (maximal weight that can be
lifted 6–12 times). In addition, the ILRT group undertook home training
twiceweekly that consisted of two to four rotations of skipping/hopping/
leaping/drop jumping [11]. ART underwent supervised exercise in the
clinic twice weekly for the initial 6 mo. The aerobic-based component
consisted of 20–30 min of exercise at 60–75% of estimated maximal
heart rate using various modes which included walking/jogging and
cycling or rowing on stationary ergometers. Resistance exercise during
the initial 6 mo was the same as that undertaken in the ILRT regimen. In
addition, participants were encouraged to undertake home-based
aerobic activity such as walking or cycling with the goal to accumulate
150 min/wk of aerobic activity. For the 2nd 6mo, patients were provided
with a home-based maintenance program similar to our previous report
[12]. DEL were provided with a printed booklet with information about
exercise for the initial 6mo, followed by 6mo of twiceweekly supervised
exercise on a cycle ergometer at an intensity of70%maximal heart rate
and flexibility exercises in the clinic. During the 12-mo study period,
ILRT, ART, and DEL were asked to maintain customary physical activity
and dietary patterns.
2.4. Fatigue and vitality
Study endpoints of fatigue and vitality were assessed at baseline, 6 mo,
and 12 mo. Fatigue was assessed using the European Organisation for
Research and Treatment of Cancer Quality of Life Questionnaire Core 30
(EORTC QLQ-C30; Table 1). Fatigue is a three-item symptom subscale
with higher scores representing greater fatigue [13]. Vitality (energy
level and fatigue) was assessed with the Short Form-36 Health Survey
(SF-36; Table 1) [14]. The Vitality scale of the SF-36 is a four-item
subdomain measure with scores ranging from 0 to 100, with higher
values indicting more vitality [15].
Patient summary: We compared the effects of different exercise modes on fatigue in men
on androgen deprivation therapy. All exercise programs reduced fatigue and enhanced
vitality. We conclude that undertaking some form of exercise will help reduce fatigue,
especially in those who are the most fatigued.
# 2017 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.5. Other measures
The 400-m walk was used as a measure of cardiovascular fitness
[5,12,16] and muscle strength was assessed using the 1-RM method
[17]. Strength is reported as the sum of the chest press and leg press,
representative of upper- and lower-body strength, respectively. Percent
body fat was determined using dual-energy x-ray absorptiometry. PSA
and total testosterone were assessed by an accredited laboratory.
Nutritional status was assessed by the Mini Nutritional Assessment [18]
and self-reported physical activity by the Leisure Score Index of the
Godin Leisure-Time Exercise Questionnaire [19].
2.6. Statistical analyses and sample size calculation
The sample size estimate for the RCT was based on projected changes in
the primary outcomes of bone mineral density and cardiorespiratory
capacity [11]. To achieve 90% power at an a level of 0.05 (two-tailed) and
account for an attrition rate of up to 35%, 65 patients per group were
required. For fatigue and vitality, assuming a minimally important
difference (MID) of 5 points for fatigue [20] and for vitality [21], 
69 patients per group were required for fatigue (51 patients for 80%
power), and  42 patients per group for vitality. Data were analysed
using IBM SPSS Version 21 (IBM Corp., Armonk, NY, USA). Analyses
included standard descriptive statistics, chi-square, one-way analysis of
variance, and one-way and two-way (group x time) repeated measures
analysis of variance. Follow-up tests were performed if the interaction or
main effect for time was significant. Where appropriate, the Bonferroni
post-hoc procedure for multiple comparisons was used to locate the
source of significant differences. Trend analysis was performed using
linear regression and entering quartiles of fatigue and vitality at baseline
as an ordinal variable. Intention to treat was utilised for all analyses
using maximum likelihood imputation of missing values (expectation
maximisation). Tests were two-tailed with an a level of 0.05 applied as
the criterion for statistical significance.
3. Results
3.1. Patients characteristics
There were no significant differences among groups at
baseline (Table 2). Themedian (interquartile range) time for
entry into the study since diagnosis was 8 (4–73) mo, 9 (4–
47) mo, and 8 (4–40) mo, and for time on ADT 3 (2–4) mo, 3
(2–4) mo, and 2 (2–4) mo for ILRT, ART, and DEL,
respectively. Of the 163 participants, four men had missing
data at baseline for both fatigue and vitality resulting in a
study group of 159 men in this report. Of these 159 parti-
Table 2 – Participant characteristics (meanW standard deviation)
ILRT ART DEL
(n = 57) (n = 54) (n = 48) p value
Age (y) 68.9  9.1 69.0  9.3 68.4  9.1 0.947
Height (cm) 173.6  5.8 173.2  6.8 171.6  5.2 0.215
Weight (kg) 84.4  11.2 84.9  15.6 88.4  15.4 0.316
Body fat (%) 28.1  4.8 27.3  5.9 29.6  5.0 0.086
Gleason score 7.7  1.4 8.0  0.9 7.8  1.0 0.548
Cancer stage grouping
Localised, N (%) 52 (91.2) 50 (92.6) 45 (93.8) 0.887
Nodal metastases, N (%) 5 (8.8) 4 (7.4) 3 (6.3)
Bone metastases, N (%) 0 (0) 0 (0) 0 (0)
PSA (ng/ml) 1.3  2.1 1.0  1.8 1.3  2.4 0.730
Testosterone (pg/ml) 0.8  1.1 1.1  2.6 1.3  3.4 0.536
MNA 27.2  2.3 27.6  2.2 27.6  1.8 0.633
Godin LSI 20.6  16.5 23.5  20.7 21.8  16.0 0.698
Employed, N (%) 22 (38.6) 17 (31.5) 19 (39.6) 0.571
Married, N (%) 44 (77.2) 42 (77.8) 43 (89.6) 0.720
Current smoker, N (%) 3 (5.3) 3 (5.6) 3 (6.3) 0.822
ADT + antiandrogen, N (%) 27 (47.4) 30 (55.6) 27 (56.3) 0.586
ADT time (mo) 4.2  4.5 5.3  7.6 3.7  3.7 0.320
Radiation, N (%) 49 (86.0) 50 (92.6) 40 (83.8) 0.341
Prostatectomy, N (%) 20 (35.1) 15 (27.8) 12 (25.0) 0.497
Other conditions
CVD, N (%) 4 (7.0) 3 (5.6) 2 (4.2) 0.819
Hypertension, N (%) 20 (35.1) 15 (27.8) 23 (47.9) 0.104
Dyslipidaemia, N (%) 11 (19.3) 14 (25.9) 10 (20.8) 0.682
Diabetes, N (%) 5 (8.8) 7 (13.0) 8 (16.7) 0.475
ADT = androgen deprivation therapy; ART = aerobic + resistance training; DEL = usual care/delayed exercise; ILRT = impact-loading + resistance training;
LSI = Leisure Score Index; PSA = prostate specific antigen; MNA = Mini Nutritional Assessment with malnourished <17, undernourished 17–23.5, well-
nourished >23.5; Godin LSI, with a moderate-to-strenuous LSI 24 classed as active and 23 classed as insufficiently active.
Table 1 – Fatigue subscale questions from the European
Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 36 and the Vitality scale questions from the
Short Form-36 Health Survey
Fatigue subscale questions
During the past wk (4-point scale from ‘‘Not At All’’ to ‘‘Very Much’’):
Did you need to rest?
Have you felt weak?
Were you tired?
Vitality scale questions
How much of the time during the past 4 wk (5-point scale from
‘‘All of the Time’’ to ‘‘None of the Time’’):
Did you feel full of life?
Did you have a lot of energy?
Did you feel worn out?
Did you feel tired?
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cipants, three men had missing data for fatigue and one
participant had missing data for vitality, resulting in
156 participants for fatigue and 158 for vitality in the
analyses. Men in the study were primarily, if not all,
Caucasian. During the trial, 34 men in ILRT, 31 in ART, and
29 in DEL received radiation therapy in conjunction with
ADT (p = 0.949). No men were on or progressed during the
trial to chemotherapy. In the 1st 6 mo of the study 37 men
withdrew with an additional 19 at 12 mo for a total of
56 men (Fig. 1). Nutritional status did not differ among
groups over the 12-mon period (p = 0.245) nor was there a
significant interaction for physical activity among groups
(p = 0.063). There was no significant change in PSA
(p = 0.103) or testosterone (p = 0.083) during the study
period. Attendance at the supervised sessions was 65% and
69% for ILRT at 6mo and 12mo, respectively, 69% for ART for
the 1st 6-mo period, and 63% for DEL for the 6–12 mo
period.
3.2. Fatigue and vitality
There was no difference among groups for fatigue
(p = 0.498) or vitality (p = 0.723) at baseline (Table 3). With
training, there was no significant interaction (p = 0.304) but
a significant effect for time (p < 0.001) with fatigue reduced
(p = 0.005) in ILRT at 6 mo and 12 mo by 5 points, and in
ART (p = 0.005) and DEL (p = 0.022) by 5 points at 12 mo.
Similarly, there was no significant interaction (p = 0.525)
but a significant effect for time (p < 0.001) with vitality
increasing for all groups (p  0.001) at 12 mo by 4 points.
There was no change in fatigue or vitality during the initial
6-mo usual care period for DEL. When levels of fatigue and
vitality were examined by quartiles, those with the highest
levels of fatigue and lowest levels of vitality at baseline
responded the best to exercise such that there was a
progressive decrease in fatigue (ptrend < 0.001) and increase
[(Fig._1)TD$FIG]
Potenal parcipants assessed for eligibility (n = 293)
Excluded (n = 130)
• Declined to parcipate (n = 28)
• Too far to travel (n = 19)
• Unable to fit in with work (n = 7)
• Unable to obtain GP consent (n = 13)
• Ineligible (bone mets) (n = 9)
• Other (n = 54)
Randomised (n = 163)
Allocated to resistance/cardiovascular (n = 54) Allocated to usual care (n= 51)
Disconnued intervenon (n = 7)
• Health (n = 1)
• Injury (n = 1)
• No longer interested in parcipang (n = 1)
• Ineligible (bone mets) (n = 2)
• Other (n = 2)
Disconnued intervenon (n = 10)
• Poor health (n = 1)
• Injury (n = 1)
• No longer interested in 
parcipang (n = 1)
• Moved away (n = 1)
• Unable to contact (n = 2)
• Family Issues (n = 1)
• Other (n = 3)
ITT analysed (n = 54)
Disconnued intervenon (n = 15)
• Health (n = 3)
• Injury (n = 3)
• No longer interested in parcipang (n = 4)
• Moved away (n = 1)
• Deceased (n = 2)
• Other (n = 2)
Disconnued intervenon (n = 5)
• Poor health (n = 2)
• Moved away (n = 1)
• Other (n = 2)
ITT analysed (n = 57)
6 mo 6 mo
12 mo 12 mo
ITT analysed (n = 48) 
Lost to follow-up (n = 15)
• Health (n = 1)
• Injury (n = 2)
• No longer interested in parcipang (n = 4)
• Moved away (n = 1)
• Deceased (n = 1)
• Unable to contact (n = 1)
• Ineligible (bone mets) (n = 1)
• Personal issues (n = 1)
• Other (n = 3)
Lost to follow-up (n = 4)
• Poor health (n = 1)
• No longer interested in parcipang (n = 2)
• Work commitments (n = 1)
Missing data (n = 1) Missing data (n = 3)
Allocated to resistance/impact loading (n = 58)
Fig. 1 – Consolidated standards of reporting trials diagram.
ITT = intention to treat; Mets = metastasis.
Table 3 – Fatigue and vitality at baseline, 6 mo, and 12 mo
Baseline 6 mo 12 mo p value
Fatigue
ILRT 27.9  20.7 22.2  15.4 22.5  16.6 0.005 B > 6, 12
ART 23.4  18.1 21.9  18.4 17.7  15.0 0.005 B, 6 > 12
DEL 25.8  20.2 24.6  17.7 20.3  15.3 0.022 B, 6 > 12
Vitality
ILRT 50.0  10.8 51.9  8.0 54.6  8.5 <0.001 B, 6 < 12
ART 51.5  10.7 52.7  9.8 55.3  8.7 0.001 B, 6 < 12
DEL 50.3  10.0 50.1  9.7 53.9  8.1 <0.001 B, 6 < 12
ART = aerobic + resistance training; B = baseline; DEL = usual care/delayed
exercise; ILRT, impact-loading + resistance training.
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in vitality (ptrend < 0.001) with exercise (Fig. 2). Sensitivity
analysis was conducted using complete cases [22] with no
change in the results for vitality and although for fatigue
there was a significant main effect for time (p = 0.003) with
the magnitude of difference within groups over time
similar, with the reduction in sample size and hence
statistical power the only significant difference was for ART
(p = 0.032).
3.3. Other measures and adverse events
For cardiorespiratory fitness, there was no significant
interaction (p = 0.216) but a significant effect for time
(p < 0.001) with fitness improved (p = 0.008) in ILRT at
12 mo by 14 s and in ART (p < 0.001) by 13 s at 12 mo,
with the change in DEL of 11 s at 12 mo approaching
significance (p = 0.063; Table 4). Notably, there was no
change in cardiorespiratory fitness during the nonexercise
period for DEL. For muscle strength, there was a significant
interaction (p < 0.001) with strength progressively increas-
ing at 6mo and 12mo (p < 0.001) in ILRT, increasing during
the initial 6-mo supervised phase in ART (p < 0.001)with no
change thereafter, and no change between baseline and
6 mo in DEL but a difference by 12 mo following exercise
(p < 0.001). No adverse effects from exercise resulted in any
participants having to withdraw from the study. Two men
in ILRT withdrew within the 1st 6 mo due to compressed
spinal discs and shoulder issues, although the person
developed shoulder issues prior to commencing exercise
training. Twomen in ART had cardiovascular problems, one
in the 1st 6 mo and one in the 2nd 6 mo, with one requiring
heart bypass surgery while another participant in ART
developed back pain. Two men withdrew from DEL in the
1st 6 mo due to difficulty walking and the other required
back surgery.
4. Discussion
To our knowledge, this is the first year-long RCT to evaluate
the effects of different exercise modalities on fatigue in
prostate cancer patients undergoing ADT. There were two
important findings: (1) all exercise modalities (resistan-
ce + impact loading, aerobic + resistance, aerobic only) had
a beneficial effect on fatigue and vitality, and (2) those with
the highest levels of fatigue and lowest vitality improved
the most with exercise.
A substantial proportion of PCa patients will receive ADT
as part of their treatment. Prevalence of clinically-relevant
fatigue in these patients has been reported as 40%
[2,23]. The fatigue scores from the EORTC QLQ-C30 in our
cohort are similar to the reference values for men with PCa
aged 60–69 y (25.2  26.6) [24]. Vitality has also been shown
to decline during ADT. In a population-based sample of men
with PCa followed for 1 y, Alibhai et al [25] reported vitality
was substantially lower in ADT-treated compared with non-
ADT patients. A more recent prospective study also showed
changes in vitality following 12mo of ADTwith rapid declines
during the initial 3 mo [26].
Short-term exercise trials have shown the efficacy of
combined resistance and aerobic exercise, or as sole training
modes, to improve fatigue in men undergoing radiation
therapy/ADT for PCa [5,7,8]. We have also shown improve-
ments in vitality following a 12-wk exercise intervention
[5]. Here we extend these findings by providing data on the
largest exercise trial undertaken with men undergoing ADT
[(Fig._2)TD$FIG]
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Fig. 2 – Change in fatigue (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 36) and vitality (Short
Form-36) with 6–12 mo exercise according to baseline status. Quartile 1 (Q1) least fatigued and highest vitality to quartile 4 (Q4) most fatigued and
least vitality. Fatigue cut-points were 22 for Q2, 33 for Q3, and 44 for Q4. For vitality, cut-points were 58 for Q2, 51 for Q3, and 44 for Q4. The p value
is for trend analysis.
Table 4 – Cardiovascular fitness and muscle strength at baseline,
6 mo, and 12 mo
Baseline 6 mo 12 mo p value
Cardiovascular fitness (s)
ILRT 274.6  56.1 264.3  47.7 260.8  48.7 0.008 B > 12
ART 269.6  50.9 254.8  41.7 256.8  47.7 <0.001 B > 12
DEL 278.8  52.5 276.3  53.8 268.3  47.1 0.063
Muscle strength (kg)
ILRT 161.2  57.6 188.9  63.5 199.4  65.5 <0.001 B<6<12
ART 163.8  61.3 193.5  66.0 191.8  64.8 0.001 B< 6, 12
DEL 168.8  73.7 177.1  70.0 187.5  76.8 <0.001 B < 12
ART = aerobic + resistance training; B = baseline; DEL = usual care/delayed
exercise; ILRT = impact-loading + resistance training.
Cardiovascular fitness determined by the 400-m walk; muscle strength
equals the sum for the chest press and leg press exercises.
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for PCa by examining the long-term effects of exercise and
potential impact of different exercise modalities. We found
that all exercise modalities had a similar effect on fatigue
and vitality following the intervention. In a recent
systematic review on fatigue instruments, theMID reported
for the EORTC QLQ-C30 ranged from 3.0–19.7 points
[20]. The mean differences for our exercise regimens was
5 points with those in quartiles 3 and 4 at baseline having
a change of 10 or more points. Similarly, it has been
recommended that the MID in vitality using the SF-36 is
5 points [21]. Themean change for each of the three exercise
regimens was 4 points, with quartiles 3 and 4 gaining a
mean of 5 points or more. This result is important as it
provides practical information to guide the prescription of
exercise in menwith PCa tomitigate cancer-related fatigue.
We have recently reported that only 12% of Australian
PCa survivors are meeting sufficient exercise levels [27]. It
appears that supervised exercise undertaken at moderate- to
high-intensity, irrespective of modality (eg, aerobic, resis-
tance, or impact) has a beneficial effect on fatigue. Moreover,
those with higher levels of fatigue/lower levels of vitality
responded the best to exercise such that there was a
progressive decrease in fatigue and increase in vitality with
exercise. As a result, fatigued patients are likely to benefit
most from any form of structured supervised exercise when
undertaken at appropriate intensity and dose. From this we
propose that screening patients on ADT for fatigue and
directing tailored and prescribed exercise interventions to
thesemen should be part of the prostate cancer care pathway.
During the nonexercise period for the delay group there
was no change in fatigue or vitality and no change in
cardiorespiratory fitness or muscle strength. Conversely,
with exercise improvements were observed in physical
functioning as they were in ILRT and ART, and these were
accompanied by changes in fatigue and vitality. Cardiore-
spiratory fitness changes as determined by the 400-m walk
[28], although not substantial [16], would at least provide a
greater safety margin before thresholds for disability are
encountered, hence may potentially be clinically meaning-
ful (especially for men in poorer condition than those in the
present study).
Our study has several features that are worthy of
comment. This is the largest and longest exercise trial in
PCa patients undergoing ADT examining different exercise
modalities including resistance, impact loading and aerobic
training. Fatigue was assessed using the EORTC QLQ-C30
fatigue subscale which is a validated measure, widely used,
and recommended for use in trials to measure cancer-
related fatigue [29]. However, the generalisability of the
data may be limited given that participants volunteered to
participate in an exercise trial, were generally quite healthy,
and predominantly were married and nonsmokers. In
addition, a potential confounding factor was the group
nature of the supervised sessions resulting in the sharing of
common experiences and the camaraderie which may have
developed, impacting on the outcomes of the study. Finally,
men in this study were primarily in the initial year of ADT,
therefore results may not be generalisable to men receiving
ADT for a longer duration.
5. Conclusions
In conclusion, in the largest year-long exercise interven-
tion study in men with PCa undergoing ADT, all exercise
programs had comparable effects on reducing fatigue and
enhancing vitality. However, the benefits were small to
nonexistent for those least fatigued at baseline and as
such an involved intervention should primarily be
considered for those who are most fatigued. Encouraging
fatigued patients to undertake exercise at adequate
intensity, regardless of mode, will likely aid in reducing
or attenuating the adverse effects of ADT on fatigue and
vitality. Screening all men on ADT for fatigue and
providing an exercise intervention is warranted.
Author contributions: Dennis R. Taaffe had full access to all the data in
the study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Taaffe, Newton, Spry, Joseph, Galva˜o.
Acquisition of data: Taaffe, Newton, Wall, Bolam, Galva˜o.
Analysis and interpretation of data: Taaffe, Newton, Spry, Galva˜o.
Drafting of the manuscript: Taaffe, Newton, Spry, Galva˜o.
Critical revision of the manuscript for important intellectual content: Taaffe,
Newton, Spry, Joseph, Gardiner, Chambers, Bolam, Wall, Cormie, Galva˜o.
Statistical analysis: Taaffe, Newton, Galva˜o.
Obtaining funding: Taaffe, Newton, Spry, Joseph, Gardiner, Galva˜o.
Administrative, technical, or material support: None.
Supervision: None.
Other: None.
Financial disclosures: Dennis R. Taaffe certifies that all conflicts of
interest, including specific financial interests and relationships and
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consul-
tancies, honoraria, stock ownership or options, expert testimony,
royalties, or patents filed, received, or pending), are the following:
None.
Funding/Support and role of the sponsor: This study was funded by the
National Health and Medical Research Council 534409, Prostate
Cancer Foundation of Australia, Cancer Council of Western Australia,
and Cancer Council of Queensland. The sponsors did not participate in
the design or conduct of the study; collection, management, analysis,
and interpretation of the data; or in the preparation, review, or
approval of the manuscript. Daniel A. Galva˜o is funded by a Cancer
Council Western Australia Research Fellowship. Suzanne Chambers is
supported by an Australian Research Council Professorial Future
Fellowship.
A phase 3 clinical trial of exercise modalities on treatment side-effects in
men receiving therapy for prostate cancer; ACTRN12609000200280
References
[1] Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen
deprivation therapy and strategies to mitigate them. Eur Urol
2014;67:825–35.
[2] Storey DJ, McLaren DB, Atkinson MA, et al. Clinically relevant
fatigue in men with hormone-sensitive prostate cancer on long-
term androgen deprivation therapy. Ann Oncol 2012;23:1542–9.
[3] Schmitz KH, Courneya KS, Matthews C, et al. American College of
Sports Medicine roundtable on exercise guidelines for cancer sur-
vivors. Med Sci Sports Exerc 2010;42:1409–26.
E U RO P E AN URO LOG Y 7 2 ( 2 0 1 7 ) 2 9 3 – 2 9 9298
[4] Bourke L, Smith D, Steed L, et al. Exercise for men with prostate
cancer: a systematic review and meta-analysis. Eur Urol
2016;69:693–703.
[5] Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined
resistance and aerobic exercise program reverses muscle loss in
men undergoing androgen suppression therapy for prostate cancer
without bone metastases: a randomized controlled trial. J Clin
Oncol 2010;28:340–7.
[6] Cormie P, Galvao DA, Spry N, et al. Can supervised exercise prevent
treatment toxicity in patients with prostate cancer initiating an-
drogen-deprivation therapy: a randomised controlled trial. BJU Int
2015;115:256–66.
[7] Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men
receiving androgen deprivation therapy for prostate cancer. J Clin
Oncol 2003;21:1653–9.
[8] Segal RJ, Reid RD, Courneya KS, et al. Randomized controlled trial of
resistance or aerobic exercise inmen receiving radiation therapy for
prostate cancer. J Clin Oncol 2009;27:344–51.
[9] Bourke L, Gilbert S, Hooper R, et al. Lifestyle changes for improving
disease-specific quality of life in sedentary men on long-term
androgen-deprivation therapy for advanced prostate cancer: a
randomised controlled trial. Eur Urol 2014;65:865–72.
[10] Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM. Lifestyle
intervention in men with advanced prostate cancer receiving an-
drogen suppression therapy: a feasibility study. Cancer Epidemiol
Biomarkers Prev 2011;20:647–57.
[11] Newton RU, Taaffe DR, Spry N, et al. A phase III clinical trial of
exercise modalities on treatment side-effects in men receiving
therapy for prostate cancer. BMC Cancer 2009;9:210.
[12] Galvao DA, Spry N, Denham J, et al. A multicentre year-long
randomised controlled trial of exercise training targeting physical
functioning in men with prostate cancer previously treated with
androgen suppression and radiation from TROG 03.04 RADAR. Eur
Urol 2014;65:856–64.
[13] Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organi-
zation for Research and Treatment of Cancer QLQ-C30: a quality-of-
life instrument for use in international clinical trials in oncology. J
Natl Cancer Inst 1993;85:365–76.
[14] Ware Jr JE, Sherbourne CD, The MOS. 36-item short-form health
survey (SF-36). I. Conceptual framework and item selection. Med
Care 1992;30:473–83.
[15] Ware Jr JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B,
Maruish ME. User’s Manual for the SF-36v2 Health Survey. ed. 2
Rhode Island: QualityMetric Incorporated; 2008.
[16] Newman AB, Simonsick EM, Naydeck BL, et al. Association of long-
distance corridor walk performance with mortality, cardiovascular
disease, mobility limitation, and disability. JAMA 2006;295:
2018–26.
[17] Taaffe DR, Duret C, Wheeler S, Marcus R. Once-weekly resistance
exercise improves muscle strength and neuromuscular perfor-
mance in older adults. J Am Geriatr Soc 1999;47:1208–14.
[18] Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment
(MNA) and its use in grading the nutritional state of elderly
patients. Nutrition 1999;15:116–22.
[19] Godin G, Shephard RJ. A simple method to assess exercise behavior
in the community. Can J Appl Sport Sci 1985;10:141–6.
[20] Nordin A, Taft C, Lundgren-Nilsson A, Dencker A. Minimal impor-
tant differences for fatigue patient reported outcome measures-a
systematic review. BMC Med Res Methodol 2016;16:62.
[21] Thabane L, Mbuagbaw L, Zhang S, et al. A tutorial on sensitivity
analyses in clinical trials: the what, why, when and how. BMC Med
Res Methodol 2013;13:92.
[22] Gavin AT, Drummond FJ, Donnelly C, O’Leary E, Sharp L, Kinnear HR.
Patient-reported ‘‘ever had’’ and ‘‘current’’ long-term physical
symptoms after prostate cancer treatments. BJU Int 2015;116:
397–406.
[23] Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 reference
values. Brussels, Belgium: EORTC Quality of Life Group; 2008.
[24] Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following
localized prostate cancer treated initially with androgen depriva-
tion therapy or no therapy. J Natl Cancer Inst 2002;94:430–7.
[25] Alibhai SM, Breunis H, Timilshina N, et al. Impact of androgen-
deprivation therapy on physical function and quality of life in men
with nonmetastatic prostate cancer. J Clin Oncol 2010;28:5038–45.
[26] Bjorner JB, Wallenstein GV, Martin MC, et al. Interpreting score
differences in the SF-36 Vitality scale: using clinical conditions and
functional outcomes to define the minimally important difference.
Curr Med Res Opin 2007;23:731–9.
[27] Galva˜o DA, Newton RU, Gardiner RA, et al. Compliance to exercise-
oncology guidelines in prostate cancer survivors and associations
with psychological distress, unmet supportive care needs, and
quality of life. Psycho-Oncology 2015;24:1241–9.
[28] Simonsick EM, Fan E, Fleg JL. Estimating cardiorespiratory fitness in
well-functioning older adults: treadmill validation of the long
distance corridor walk. J Am Geriatr Soc 2006;54:127–32.
[29] Minton O, Stone P. A systematic review of the scales used for the
measurement of cancer-related fatigue (CRF). Ann Oncol
2009;20:17–25.
E U RO P E AN URO L OGY 7 2 ( 2 0 1 7 ) 2 9 3 – 2 9 9 299
